This is ideal for anyone who does not like the idea of injecting themselves
For people who use semaglutide for blood sugar management (type 2 diabetes), the stakes of using degraded medication are arguably higher than for weight management alone
Importantly, never reduce or stop insulin abruptly when starting GLP-1 therapy, as this carries a risk of diabetic ketoacidosis
Safety and Tolerability Both compounds share a dominant, mostly mild-to-moderate gastrointestinal adverse-event profile nausea, vomiting, diarrhea, constipation, abdominal pain concentrated during dose escalation
Monitor Your Response: Track changes in appetite, weight trends, and side effects
It is not a biologic, so it does not need the more complex biosimilar pathway